5.2.7.1. α1-blockers + 5α-reductase inhibitors. mechanism action: combination therapy consists α1-blocker (section 5.2.1) together 5-ari (section 5.2.2). α1-blocker exhibits clinical effects within hours days, whereas 5-ari needs several months develop full clinical efficacy. finasteride tested clinical trials alfuzosin, terazosin, doxazosin terazosin, dutasteride tamsulosin. efficacy: several studies investigated efficacy combination therapy α1-blocker, 5-ari, placebo alone. initial studies follow-up periods six twelve months demonstrated α1-blocker superior finasteride symptom reduction, whereas combination therapy agents superior α1-blocker monotherapy . studies placebo arm, α1-blocker consistently effective placebo, finasteride not. data one year mtops study showed similar results . long-term data (four years) mtops combat studies showed combination treatment superior monotherapy symptoms qmax, superior α1-blocker alone reducing risk aur need surgery . combat study demonstrated combination treatment superior either monotherapy regarding symptoms flow rate starting month nine, superior α1-blocker aur need surgery eight months . thus, differences mtops may reflect different inclusion exclusion criteria baseline patient characteristics. discontinuation α1-blocker six nine months combination therapy investigated rct open-label multicentre trial . first trial evaluated combination tamsulosin dutasteride impact tamsulosin discontinuation six months , almost three quarters patients reporting worsening symptoms. however, patients severe symptoms (ipss > 20) baseline may benefit longer combination therapy. recent trial evaluated symptomatic outcome finasteride monotherapy three nine months discontinuation nine-month combination therapy . lower urinary tract symptom improvement combination therapy sustained three months (ipss difference 1.24) nine months (ipss difference 0.4). limitations studies include short duration short follow-up period discontinuation. mtops combat studies, combination therapy superior monotherapy preventing clinical progression defined ipss increase least four points, aur, uti, incontinence, increase creatinine > 50%. mtops study found risk long-term clinical progression (primarily due increasing ipss) reduced 66% combined therapy vs. placebo greater extent either finasteride doxazosin monotherapy (34% 39%, respectively) . addition, finasteride (alone combination), doxazosin alone, significantly reduced risks aur need bpo-related surgery four-year study. combat study, combination therapy reduced relative risks aur 68%, bpo-related surgery 71%, symptom deterioration 41% compared tamsulosin, four years . prevent one case urinary retention and/or surgical treatment, thirteen patients need treated four years dutasteride tamsulosin combination therapy compared tamsulosin monotherapy absolute risk reduction (risk difference) 7.7%. conduct study compared efficacy safety fixed-dose combination dutasteride tamsulosin ww approach potential initiation tamsulosin (step-up approach) two-year rct total 742 patients. arms detailed lifestyle advice given. fixed-dose combination resulted rapid sustained improvement men moderate luts risk disease progression, difference ipss 24 months 5.4 active arm 3.6 placebo arm . furthermore, tamsulosin plus dutasteride significantly reduced relative risk clinical progression (mainly characterised worsening symptoms) 43.1% compared ww, absolute risk reduction 11.3% (number needed treat [nnt] = 9). influence baseline variables changes ipss combination therapy dutasteride plus tamsulosin either monotherapy tested based four-year results combat study. combination therapy provided consistent improvement luts tamsulosin across analysed baseline variables 48 months . combination 5-ari finasteride tadalafil 5 mg tested large scale rct finasteride monotherapy. study supports concept novel combination therapy described detail section 5.2.5 . tolerability safety: adverse events drug classes reported combination treatment . adverse events observed combination treatment typical α1-blockers 5-aris. frequency adverse events significantly higher combination therapy. mtops study demonstrated incidence treatment related adverse events higher first year combined treatment doxazosin finasteride . meta-analysis measuring impact medical treatments luts/bph ejaculatory function, reported combination therapy α1-blockers 5-aris resulted three-fold increased risk ejd compared monotherapy . practical considerations: compared α1-blockers 5-ari monotherapy, combination therapy results greater improvement luts increase qmax superior prevention disease progression. however, combination therapy also associated higher rate adverse events. combination therapy therefore prescribed primarily men moderate-to-severe luts risk disease progression (higher prostate volume, higher psa concentration, advanced age, higher pvr, lower qmax, etc.). combination therapy used long-term treatment (more twelve months) intended, patients informed this. discontinuation α1-blocker six months might considered men moderate luts. summary evidencelelong-term data (four years) mtops combat studies showed combination treatment superior monotherapy symptoms qmax, superior α1-blocker alone reducing risk aur need surgery.1bthe mtops study found risk long-term clinical progression (primarily due increasing ipss) reduced 66% combined therapy vs. placebo greater extent either finasteride doxazosin monotherapy.1bthe combat study found combination therapy reduced relative risks aur 68%, bph-related surgery 71%, symptom deterioration 41% compared tamsulosin, four years.1badverse events drug classes seen combined treatment using α1-blockers 5-aris.1b recommendationstrength ratingoffer combination treatment α1-blocker 5α-reductase inhibitor men moderate-to-severe luts increased risk disease progression (e.g. prostate volume > 40 ml).strong